David A. Siegel Elevation Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 84,400 shares of ELEV stock, worth $43,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
84,400
Previous 57,100
47.81%
Holding current value
$43,044
Previous $34,000
41.18%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ELEV
# of Institutions
71Shares Held
39.1MCall Options Held
100Put Options Held
3.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.06 Million0.21% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$2.43 Million0.21% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$1.8 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA2.97MShares$1.51 Million0.06% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.45 Million0.6% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $11.9M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...